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Abstract
Multiple sclerosis is a neurological disease that affects millions of people worldwide, yet is not entirely understood.
Symptoms of multiple sclerosis most frequently include muscle spasms and extreme fatigue, but patients can experience
a wide variety of issues. There are four categories in which
patients with multiple sclerosis are typically classified: relapse-remitting, primary-progressive, secondary-progressive
and progressive-relapsing. The pathophysiology of the disease is largely unknown, but many theories are being researched. Currently, there are treatments that can alleviate
symptoms and halt disease progression, but no cure is
known at this time. Most symptomatic relief medications
focus on anti-inflammatory mechanisms of action, while disease modifying treatments have novel mechanisms which
are being studied more fully. By being aware of new drug
therapies, pharmacists can better counsel patients with this
disease state. As new therapies are approved, it is important
to understand their mechanism and reasons for use, so as to
be aware of potential side effects and interactions.
Introduction to Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory neurological disease that affects 2.1 million people worldwide including about 400,000 AmericansP An estimated 200 Americans
are diagnosed with MS every week. 2 The hallmark of MS is a
progressive autoimmune-mediated demyelination of neurons. The myelin sheath acts as an insulator, providing high
resistance and low capacitance, resulting in greater impulse
conduction velocity of neurons.3 Thus, demyelination leads
to slowed or blocked signal transmission. MS is characteristically idiopathic, in that a defined pathophysiology has not
been determined. However, studies suggest a strong genetic
influence, as first-degree relatives of an affected individual
are 20 times more likely to be diagnosed with MS than the
general population. In addition, case studies have found that
patients with MS have elevated levels of antibodies targeting
Epstein-Barr virus proteins, suggesting the virus may initiate
inflammatory responses that lead to autoimmune demyelination, characteristic of MS.4-6 The onset of symptoms and diagnosis typically occurs between the ages of 20 and 50; women
are two to three times more likely to be affected by MS than
men.
Symptoms
The symptoms of MS are common to many neurologic disorders and are erratic, affecting the muscles, bowel, bladder,
eyes, brain and spine.6 The most frequent symptoms associated with MS are fatigue and muscle spasticity. However,
affected individuals may also experience muscle stiffness,
disequilibrium, paralysis of the limbs and bowel, mood and
behavioral changes such as depression, impaired vision,
slurred speech and incontinence. Symptoms range in inten-
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sity from mild to severe, with high inter-patient variability.
The degree of discomfort and disability associated with MS
depends on the frequency and severity of attacks, and the
area of the nervous system affected. MS is typically identified
by differential diagnosis due to high variability in patient
presentation and symptom commonality with other neurologic disorders.2
Effective management of symptoms improves quality of life
and is imperative to prevent permanent damage that can
result in disease progression and worsening symptoms.1
Pharmacological treatments may include corticosteroids to
decrease inflammation in nervous tissue and reduce the duration and severity of flare-ups. Muscle relaxants, such as
tizanidine (Zanaflex®) or baclofen (Lioresel®), reduce stiffness and muscle spasticity. Plasma exchange may also be
used for patients who do not benefit from corticosteroid
therapy and experience sudden, severe attacks of MS-related
disability. The antiviral drug amantadine (Symmetrel®) or
the stimulant modafinil (Provigil®) may be used for fatiguelike symptoms. An anticholinergic medication such as
tolterodine (Detrol®) may be used for incontinence by blocking contractions of the bladder.6 Since mood and behavioral
symptoms are also common, antidepressants can be used in
MS patients, while non-pharmacological approaches such as
physical, speech or occupational therapy may help maintain
independence in activities of daily living. Individual or group
therapy can help with the emotional stress of coping with the
disease. Assistive devices such as a wheelchair, walker or
shower chair, as well as a healthy lifestyle and planned exercise program, have also been noted to help with some of the
movement issues a patient will experience. As with many
diseases, avoiding illness, stress and fatigue with plenty of
relaxation and rest can improve symptoms.

Clinical Classification of Multiple Sclerosis
Multiple sclerosis can be loosely classified into one of four
clinical categories: relapse-remitting, primary-progressive,
secondary-progressive and progressive-relapsing.7 The following descriptions are used for the four categories:
Relapse-Remitting MS (RRMS): Patients experience bouts of
worsening neurologic function known as relapses. These
flare-ups last anywhere from a few days to months and are
contrasted by periods of remission characterized by full or
partial recovery, during which no disease progression occurs. The flare-ups must last at least 24 hours and be separated from the previous attack by at least one month. No two
flare-ups are alike. They may include just one symptom or
involve multiple symptoms. Most patients are initially diagnosed in this category but many will progress to secondaryprogressive MS.
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Primary-Progressive MS (PPMS): The hallmark of PPMS is a
worsening neurologic function from disease onset, without a
clear pattern of relapse and remission.
Secondary-Progressive MS (SPMS): This classification is an

example of the blurred boundaries between classifications
because it is difficult to clearly distinguish it from PPMS due
to their similarities. It is characterized as worsening of neurological function, with more irreversible damage occurring,
with or without flare-ups and minor relapses. Thus, over
time, symptoms associated with relapse become worse,
while remissions are less prominent and shorter in duration,
eventually becoming non-existent.
Progressive-Relapsing MS (PRMS): This classification is relatively rare. Patients experience a steady worsening of the
disease from the beginning without remissions. Patients may
experience clearly-defined relapses that may slow after some
time; however, the disease is always continuing to progress.

Pharmacotherapy
Currently no cure for MS exists; however, treatment options
are available for patients based on an anti-inflammatory
strategy to slow disease progression.1.2 First-line treatments
are intramuscular or subcutaneous interferon 13 (Rebif®) and
subcutaneous glatiramer acetate (Copaxone®), both of which
are indicated for RRMS. The exact mechanism of action of
interferon 13 is unknown. However, it has been proposed to
suppress the T-helper cell response, thereby diminishing Tcell migration across the blood-brain barrier, which reduces
the inflammatory process. Common adverse effects consist of
flu-like symptoms, depression and elevated hepatic enzymes.
The mechanism of action of glatiramer acetate is not fully
understood, but is thought to involve alteration of T-cell activation and differentiation. Common adverse effects are similar to those seen with interferon 13, including injection-site
reactions and depression, as well as lipoatrophy. These two
drugs should be avoided in patients with a coexisting depressive disorder. The BEYOND, BECOME and REGARD trials
compared the two first-line agents and found them to have
comparable efficacy, with no significant differences regarding relapse rate, disability progression or magnetic resonance imaging (MRI) outcomes.i.a.9
Second-line
agents
are
intravenous
mitoxantrone
(Novantrone®) and intravenous natalizumab (Tysabri®).2
Mitoxantrone was the first approved disease-modifying therapy indicated for multiple MS classifications (RRMS, SPMS,
PRMS).1.2 Mitoxantrone works by intercalating DNA and inhibiting topoisomerase II. This results in DNA breaks and
inhibition of DNA repair, causing reduced proliferation of Band T-cells and reduced release of inflammatory cytokines.
This agent is associated with rare but serious side effects of
cardiotoxicity and severe bone marrow suppression, thus it
is not considered a first-line agent. More common adverse
effects associated with treatment include nausea, vomiting,
alopecia and leukopenia. Mitoxantrone is used when patients
progress from RRMS to a more severe stage of MS. The other
second-line agent, natalizumab, is a humanized monoclonal
antibody that inhibits leukocytes from crossing the bloodJuly 2012 Volume 3, Issue 2
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brain barrier by antagonizing a4 integrins on leukocytes.1
This monoclonal is not a first-line agent due to its association
with progressive multifocal leukoencephalopathy (PML), a
potentially fatal infection caused by the JC polyomavirus. The
more common adverse events are headache, fatigue, allergic
reaction and infection. These two treatments are reserved
for patients who cannot tolerate or are unresponsive to firstline agents.

Emerging Therapies: FDA Approved
Two new agents were approved by the Food and Drug Administration (FDA) in 2010 for the treatment of MS, both
with novel mechanisms relative to existing therapiesdalfampridine (Ampyra®) and fingolimod (Gilenya®).3 Dalfampridine is the only FDA approved symptom management
treatment to improve walking in all types of MS. Although
there is disagreement on the exact mechanism by which dalfampridine exerts its therapeutic effects, it is classified as a
voltage-dependent potassium channel blocker that lowers
the seizure threshold. Studies showed efficacy in one-third of
patients and the most common adverse effects were falls,
urinary tract infections, insomnia, asthenia, headache, nausea and dizziness.
The second medication, fingolimod, is considered a diseasemodifying treatment, and is a sphingosine 1-phosphate
receptor modulator. In vivo, fingolimod is a prodrug which
has a phosphorylated active metabolite that exerts its therapeutic effects by decreasing the release of autoreactive lymphocytes. This lowers the amount of peripheral lymphocytes
and sequesters lymphocytes in the lymph nodes.10 There is
also potential for neuroprotective and/or reparative functions.11 Importantly, with this novel mechanism, it is the first
FDA approved oral treatment for relapsing forms of MS and
is now considered first-line treatment for RRMs.uo Fingolimod is metabolized by CYP4F2; however, drug-drug interactions are not likely because other drugs currently on the
market are not metabolized by this enzyme.10 The most common adverse effects experienced were headache, influenza,
diarrhea, back pain, liver enzyme elevations and cough.
Serious adverse events of bradycardia, MS relapse, basal cell
carcinoma and chest pain occurred in less than 1 percent of
patients. Recent reports of patient deaths after taking the
first dose of fingolimod have also led to label changes guiding
practitioners in appropriate patient populations.
The
updated FDA label for Gilenya® indicates that all patients
initiating treatment with Gilenya® should have an electrocardiogram (ECG) prior to the first dose of the medicine and
after the six-hour first-dose observation period in addition to
hourly measurement of blood pressure and heart rate.12
Additionally, specific initiation guidance for patients is now
provided to better aid health care providers. Further, there
are revised recommendations on how to re-initiate therapy
should Gilenya® be interrupted.

Emerging Therapies: New Labeling in Clinical Trials
In addition, several medications are under investigation for
new labeling in the treatment of MS that are currently approved for different indications. These are cladribine
(Leustatin®) and the monoclonal antibodies alemtuzamab
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(Campath®), daclizumab (Zenapax®) and rituximab
(Rituxan®). Cladribine was approved in 1993 for the treatment of hairy cell leukemia.13 Currently a variety of studies
exist evaluating the use of cladribine in treatment of MS as an
add-on to interferon f3 or an oral formulation.14 Cladribine is
hypothesized to exert its effects as an immunomodulatory
purine analog with lymphocytotoxic activity. This would act
by damaging DNA and thereby cause selective cell death of
lymphocytes.2 It is generally well-tolerated, with adverse
effects of headache, nasopharyngitis, upper respiratory tract
infection, urinary tract infection, alopecia and sensory
disturbances. Monoclonal antibodies exert their effects by
recognizing specific target antigens ultimately resulting in
differing immunosuppressive mechanisms. Alemtuzumab
and daclizumab are both humanized monoclonal antibodies
that are slightly less immunogenic due to only one small nonhuman portion in the complement sequence. Alemtuzumab
reduces the number of circulating T-cells, while daclizumab
antagonizes IL-2 on activated lymphocytes, which is responsible for the up-regulation of the immune system. Rituximab
is a chimeric monoclonal antibody causing more immunogenic reactions due to the presence of the murine antigenbinding domain. It exerts its effects by selectively depleting
CD20 pre-B-cells and B-cells ultimately causing cytotoxicity.
The major concern with monoclonal antibodies would be the
adverse effect profile requiring careful monitoring of their
use with other immunosuppressant medications. This concomitant use may cause depletion of multiple cell lines,
which could lead to potentially serious infections. Adverse
effects associated with these monoclonal antibodies are
systemic immune responses such as mouth ulcers, photosensitivity rash, transient formation of autoantibodies, lymphopenia, lymphadenopathy and transient increases in
bilirubin concentration.

Emerging Therapies: Orphans in Clinical Trials
Three immunomodulator medications are currently in clinical trials for new MS treatments: laquinimod, teriflunomide
and dimethyl fumarate. 2 The mechanism of action of laquinimod has not been fully defined, but is proposed to work via
immunomodulatory properties with potential neuroprotection.1s Infiltration of leukocytes into the central nervous
system (CNS) leads to destruction of white matter and neurological impairment. It is hypothesized that laquinimod acts
by reducing demyelination and axonal degeneration via
changes in the cytokine shift. Studies have shown laquinimod
to be generally well-tolerated, with minimal differences between the placebo and laquinimod groups regarding adverse
effects.2 Teriflunomide exerts its effects via anti-inflammatory
and antiproliferative properties.is Teriflunomide is the active
metabolite of leflunomide, a commonly used treatment in
rheumatoid arthritis. Thus far, it has exhibited a favorable
safety profile and efficacy in the treatment of aspects of rheumatoid arthritis that are similar to the autoimmune reaction
in MS patients. Teriflunomide exerts its effects by decreasing
activation of T-cells by antigen presenting cells.2 Dimethyl
fumarate is an orally administered immunomodulatory agent
that inhibits microglia and astrocytes via the Nrf2 signaling
pathway, resulting in reduced CNS inflammation. I The most
common side effects were abdominal pain and flushing
(Table 1).
Pharmacist's Role
With approximately 400,000 Americans diagnosed with MS,
pharmacists play a critical role in improving patient outcomes. Continued development of an increasing number of
novel treatment modalities make it imperative for pharmacists to be informed on the current therapies. In addition,
with the recent approval of oral medications to treat MS, the

Table 1. Potential Indications for Emerging MS Therapiesz
RRMS

SPMS

PPMS

Fingolimod

+

+

NR

Laquinimod

+

+

NR

Teriflunomide

+

+

NR

Dimethyl Fumarate

+

NR

NR

NR

+

+

Alemtuzumab

+

NR

NR

Daclizumab

+

+

NR

Rituximab

+

NR

+

Drug

Cladribine

NR= not reported
Adapted from Gawronski, et al. Table 3 p 921.
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role of the pharmacist is no longer limited to inpatient clinical monitoring and counseling but has expanded to include
the outpatient setting. Thus, it is increasingly likely pharmacists will be needed for the education of patients as well as
other health care professionals on current and emerging
treatments for MS.
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